Top

Journal of Hematology & Oncology

Published in:

Open Access 01-12-2013 | Short report

Induction of long intergenic non-coding RNA HOTAIR in lung cancer cells by type I collagen

Authors: Yan Zhuang, Xiang Wang, Hong T Nguyen, Ying Zhuo, Xinpeng Cui, Claire Fewell, Erik K Flemington, Bin Shan

Published in: Journal of Hematology & Oncology | Issue 1/2013

Abstract

Background

The tumor microenvironment is a crucial determinant in tumor progression. Interstitial extracellular matrix (ECM), such as type I collagen (Col-1), is aberrantly enriched in the tumor microenvironment and promotes tumor progression. Long intergenic non-coding RNAs (lincRNA) are a new family of regulatory RNAs that modulate fundamental cellular processes via diverse mechanisms.

Findings

We investigated whether the expression of lincRNAs was regulated by the tumor promoting Col-1. In a three-dimensional organotypic culture model using the reconstituted basement membrane ECM Matrigel (rBM 3-D), supplementation of Col-1 disrupted acini, a differentiation feature of well-differentiated lung adenocarcinoma cells, and concurrently induced the expression of a tumor-promoting lincRNA, HOX transcript antisense RNA (HOTAIR). Induction of HOTAIR by Col-1 was diminished by a neutralizing antibody against the Col-1 receptor α2β1 integrin. Col-1 activates the expression of a reporter gene controlled by the human HOTAIR promoter. Moreover the expression of HOTAIR and Col-1 was concurrently up-regulated in human non-small cell lung cancer.

Conclusions

Our findings indicate that tumor-promoting Col-1 up-regulates the expression of HOTAIR in NSCLC cells. These initial results warrant further investigation of HOTAIR and other lincRNA genes in lung tumorigenesis.

Available only for authorised users

Egeblad M, Rasch MG, Weaver VM: Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol. 2010, 22 (5): 697-706. 10.1016/j.ceb.2010.08.015.PubMedCentralCrossRefPubMed

Hebner C, Weaver VM, Debnath J: Modeling morphogenesis and oncogenesis in three-dimensional breast epithelial cultures. Annu Rev Pathol. 2008, 3: 313-339. 10.1146/annurev.pathmechdis.3.121806.151526.CrossRefPubMed

Lee GY, Kenny PA, Lee EH, Bissell MJ: Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods. 2007, 4 (4): 359-365. 10.1038/nmeth1015.PubMedCentralCrossRefPubMed

Yu W, Fang X, Ewald A, Wong K, Hunt CA, Werb Z, Matthay MA, Mostov K: Formation of cysts by alveolar type II cells in three-dimensional culture reveals a novel mechanism for epithelial morphogenesis. Mol Biol Cell. 2007, 18 (5): 1693-1700. 10.1091/mbc.E06-11-1052.PubMedCentralCrossRefPubMed

Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, Reinhart-King CA, Margulies SS, Dembo M, Boettiger D: Tensional homeostasis and the malignant phenotype. Cancer Cell. 2005, 8 (3): 241-254. 10.1016/j.ccr.2005.08.010.CrossRefPubMed

Li C, Nguyen HT, Zhuang Y, Lin Y, Flemington EK, Guo W, Guenther J, Burow ME, Morris GF, Sullivan D: Post-transcriptional up-regulation of miR-21 by type I collagen. Mol Carcinog. 2011, 50 (7): 563-570. 10.1002/mc.20742.CrossRefPubMed

Nguyen HT, Li C, Lin Z, Zhuang Y, Flemington EK, Burow ME, Lin Y, Shan B: The microRNA expression associated with morphogenesis of breast cancer cells in three-dimensional organotypic culture. Oncology reports. 2012, 28 (1): 117-126.PubMedCentralPubMed

Wang KC, Chang HY: Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011, 43 (6): 904-914. 10.1016/j.molcel.2011.08.018.PubMedCentralCrossRefPubMed

Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E: Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007, 129 (7): 1311-1323. 10.1016/j.cell.2007.05.022.PubMedCentralCrossRefPubMed

10.

Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010, 464 (7291): 1071-1076. 10.1038/nature08975.PubMedCentralCrossRefPubMed

11.

Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, Kim S, Safe S: HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene. 2013, 32 (13): 1616-1625. 10.1038/onc.2012.193.PubMedCentralCrossRefPubMed

12.

Niinuma T, Suzuki H, Nojima M, Nosho K, Yamamoto H, Takamaru H, Yamamoto E, Maruyama R, Nobuoka T, Miyazaki Y: Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Res. 2012, 72 (5): 1126-1136. 10.1158/0008-5472.CAN-11-1803.CrossRefPubMed

13.

Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T: Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 2001, 410 (6832): 1111-1116. 10.1038/35074129.CrossRefPubMed

14.

Shan B, Zhuo Y, Chin D, Morris CA, Morris GF, Lasky JA: Cyclin-dependent kinase 9 is required for tumor necrosis factor-alpha-stimulated matrix metalloproteinase-9 expression in human lung adenocarcinoma cells. J Biol Chem. 2005, 280 (2): 1103-1111.CrossRefPubMed

15.

Zhuang Y, Nguyen HT, Lasky JA, Cao S, Li C, Hu J, Guo X, Burow ME, Shan B: Requirement of a novel splicing variant of human histone deacetylase 6 for TGF-beta1-mediated gene activation. Biochem Biophys Res Commun. 2010, 392 (4): 608-613. 10.1016/j.bbrc.2010.01.091.PubMedCentralCrossRefPubMed

16.

Li C, Nguyen HT, Zhuang Y, Lin Z, Flemington EK, Zhuo Y, Kantrow SP, Morris GF, Sullivan DE, Shan B: Comparative profiling of miRNA expression of lung adenocarcinoma cells in two-dimensional and three-dimensional cultures. Gene. 2012, 511 (2): 143-150. 10.1016/j.gene.2012.09.093.PubMedCentralCrossRefPubMed

17.

Shan B, Yao TP, Nguyen HT, Zhuo Y, Levy DR, Klingsberg RC, Tao H, Palmer ML, Holder KN, Lasky JA: Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition. J Biol Chem. 2008, 283 (30): 21065-21073. 10.1074/jbc.M802786200.PubMedCentralCrossRefPubMed

18.

Kass L, Erler JT, Dembo M, Weaver VM: Mammary epithelial cell: influence of extracellular matrix composition and organization during development and tumorigenesis. Int J Biochem Cell Biol. 2007, 39 (11): 1987-1994. 10.1016/j.biocel.2007.06.025.PubMedCentralCrossRefPubMed

19.

Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W: Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009, 139 (5): 891-906. 10.1016/j.cell.2009.10.027.PubMedCentralCrossRefPubMed

20.

Knight CG, Morton LF, Onley DJ, Peachey AR, Messent AJ, Smethurst PA, Tuckwell DS, Farndale RW, Barnes MJ: Identification in collagen type I of an integrin alpha2 beta1-binding site containing an essential GER sequence. J Biol Chem. 1998, 273 (50): 33287-33294. 10.1074/jbc.273.50.33287.CrossRefPubMed

21.

Shan B, Morris CA, Zhuo Y, Shelby BD, Levy DR, Lasky JA: Activation of proMMP-2 and Src by HHV8 vGPCR in human pulmonary arterial endothelial cells. J Mol Cell Cardiol. 2007, 42 (3): 517-525. 10.1016/j.yjmcc.2006.08.004.CrossRefPubMed

22.

Shan B, Hagood JS, Zhuo Y, Nguyen HT, MacEwen M, Morris GF, Lasky JA: Thy-1 attenuates TNF-alpha-activated gene expression in mouse embryonic fibroblasts via Src family kinase. PLoS One. 2010, 5 (7): e11662-10.1371/journal.pone.0011662.PubMedCentralCrossRefPubMed

23.

Shan B, Morris GF: Binding sequence-dependent regulation of the human proliferating cell nuclear antigen promoter by p53. Exp Cell Res. 2005, 305 (1): 10-22. 10.1016/j.yexcr.2004.09.033.CrossRefPubMed

24.

Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT: Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet. 2006, 38 (9): 1060-1065. 10.1038/ng1855.PubMedCentralCrossRefPubMed

Title: Induction of long intergenic non-coding RNA HOTAIR in lung cancer cells by type I collagen
Authors: Yan Zhuang
Xiang Wang
Hong T Nguyen
Ying Zhuo
Xinpeng Cui
Claire Fewell
Erik K Flemington
Bin Shan
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2013
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/1756-8722-6-35

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Findings

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases

Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?

Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice

Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma

Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing

Keynote webinar | Spotlight on antibody–drug conjugates in cancer